Pancreatic Cancer

Genetic mutations accumulate over years. Most common driver: KRAS mutation. Smoking is the largest modifiable risk factor. Family history of pancreatic, breast, ovarian, or colorectal cancer increases risk.

Lifetime risk ~1 in 65. Saudi rates rising slowly. Mostly affects people over 60. Risk factors: smoking (doubles risk), chronic pancreatitis, diabetes, obesity, family history, BRCA1/2 and Lynch syndrome carriers, IPMN.

Saudi tertiary centers have high-volume pancreatic surgery programs (KFSH, KFMC, KAU). Surgical outcomes correlate strongly with surgeon volume. Several centers offer multidisciplinary tumor boards.

Triple-phase CT or MRI of the pancreas with contrast. EUS with biopsy provides tissue diagnosis. CA 19-9 blood test is a tumor marker (not specific). Staging: CT chest/abdomen/pelvis ± PET. Genetic testing if family history.

Prevention is best — reduce modifiable risks.

• Don't smoke — most important risk factor.

• Maintain healthy weight.

• Limit alcohol.

• Manage diabetes well.

• If family history of pancreatic, breast, ovarian, colorectal cancer: ask about genetic testing and surveillance.

Mediterranean pattern; for those undergoing treatment, nutrition support is critical.

• Adequate protein and calories during treatment.

• Pancreatic enzymes if exocrine insufficiency.

• See a dietitian familiar with cancer care.

Chemotherapy regimens have improved.

• FOLFIRINOX (combination chemotherapy) — first-line for fit patients with metastatic or locally advanced disease.

• Gemcitabine + nab-paclitaxel — alternative.

• Olaparib (PARP inhibitor) for BRCA-mutated tumors after platinum chemotherapy.

• Pembrolizumab for MSI-high or mismatch-repair-deficient tumors.

• Pancreatic enzyme replacement for malabsorption.

Surgery offers the only chance of cure for early disease.

• Whipple procedure (pancreaticoduodenectomy) — for tumors in the head of the pancreas.

• Distal pancreatectomy — for body/tail tumors.

• Biliary stenting via ERCP for jaundice in inoperable disease.

• Celiac plexus block for pain control.

FOLFIRINOX and gemcitabine-nab-paclitaxel chemotherapy regimens improved survival. Olaparib for BRCA-mutated tumors. Pembrolizumab for MSI-high tumors. Neoadjuvant treatment now standard for borderline-resectable disease.

Stage at diagnosis matters enormously. Stage I (resectable, found early): 5-year survival 30-40%. Stage IV: median survival 6-11 months. Most patients are diagnosed at stage III or IV. Advances in treatment are slowly improving outcomes.

• Is my tumor resectable?

• Should I have my tumor tested for BRCA, MSI, and other genetic markers?

• Should my family members be tested?

• What chemotherapy is best for me?

This guide comes from the Saudi Gastroenterology Association (SGA) patient library, prepared by the SGA Patient Education Panel. Last reviewed: 2026-04-24. It is for education and does not replace your doctor's advice.